Targeting isocitrate lyase for the treatment of latent tuberculosis
Ram Prasad Bhusal, Ghader Bashiri, Brooke XC Kwai, Jonathan Sperry, Ivanhoe KH Leung
DRUG DISCOVERY TODAY | ELSEVIER SCI LTD | Published : 2017
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis that can remain dormant for many years before becoming active. One way to control and eliminate TB is the identification and treatment of latent TB, preventing infected individuals from developing active TB and thus eliminating the subsequent spread of the disease. Isocitrate lyase (ICL) is involved in the mycobacterial glyoxylate and methylisocitrate cycles. ICL is important for the growth and survival of M. tuberculosis during latent infection. ICL is not present in humans and is therefore a potential therapeutic target for the development of anti-TB agents. Here, we explore the evidence linking ICL to persiste..View full abstract
We thank the University of Auckland for a Doctoral Scholarship (R.P.B) and the Maurice and Phyllis Paykel Trust for funding.